Sold as Aggrenox. Every FDA application for this active ingredient: 1 branded and 11 generic.
As of Nov 22, 2026, FDA lists 12 applications for Aspirin; Dipyridamole (sold as Aggrenox), first approved Nov 22, 1999, with 2 new uses approved and 0 published complete response letters.
| Nov 22, 1999 | AggrenoxNDA 20884 · New combination | Boehringer Ingelheim Pharmaceuticals | 17 | Discontinued |
| Aug 14, 2009 | Aspirin and DipyridamoleANDA 78804 | Barr Laboratories | 4 | Marketed |
| Mar 8, 2016 | Aspirin and DipyridamoleANDA 206392 | Amneal Pharmaceuticals | 3 | Marketed |
| Jan 18, 2017 | Aspirin and DipyridamoleANDA 206739 | Sandoz | 3 | Marketed |
| Jan 18, 2017 | Aspirin and DipyridamoleANDA 206964 | ANI Pharmaceuticals | 3 | Discontinued |
| Jan 18, 2017 | Aspirin and DipyridamoleANDA 207944 | PH Health | 2 | Marketed |
| Aug 29, 2017 | Aspirin and DipyridamoleANDA 206753 | Zydus Pharmaceuticals (USA) | 1 | Marketed |
| Aug 21, 2018 | Aspirin and DipyridamoleANDA 208572 | Sun Pharmaceutical Industries | 1 | Discontinued |
| Oct 10, 2018 | Aspirin and DipyridamoleANDA 209048 | Dr. Reddy's Laboratories | 3 | Marketed |
| Mar 20, 2019 | Aspirin and DipyridamoleANDA 204552 | Chartwell Molecular | 2 | Discontinued |
| May 24, 2019 | Aspirin and DipyridamoleANDA 210318 | Glenmark Specialty | 2 | Marketed |
| Aug 11, 2021 | Aspirin and DipyridamoleANDA 209929 | Micro Labs | 0 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Aspirin-Dipyridamole ER | Part D | $12.9M | −23% | 16,926 |
| Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale StudyIschemic Stroke, Patent Foramen Ovale · National University Hospital, Singapore | — | Not yet recruiting | May 21, 2025 |
| Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery StenosisAsymptomatic Carotid Artery Stenosis · Beijing Tiantan Hospital | Not applicable | Recruiting | Mar 28, 2025 |
| Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction PatientsCerebral Infarction, Chinese Herbal Medicine · Yan Zhu | Not applicable | Not yet recruiting | Aug 12, 2024 |
| Genotype Guided Antiplatelet Therapy In Ischemic StrokeIschemic Stroke, Transient Ischemic Attack · National Neuroscience Institute | Not applicable | Active, not recruiting | Mar 10, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA